Highlights Healios K.K.

Equities

4593

JP3835100003

Delayed Japan Exchange Other stock markets 12:26:40 2024-05-10 am EDT			5-day change	1st Jan Change
157 ^JPY	-1.26%		0.00%	-5.45%

Apr. 10	Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen	MT
Apr. 09	Healios K.K. Enters into Joint Research Agreement with AND Medical Group	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen	Apr. 09	MT
Healios K.K. Enters into Joint Research Agreement with AND Medical Group	Apr. 08	CI
Healios Concludes Purchase of Athersys Assets, Becoming Sole Owner of MultiStem IP	Apr. 04	MT
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .	Apr. 02	CI
Healios K.K. and ProcellCure Inc. Announce Start of ARDS Clinical Trial in Japan	Feb. 01	CI
Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan	Jan. 17	CI
Healios Secures LOI on Joint Research with AND	Jan. 17	MT
Healios K.K. AND Medical Group Enter into A Letter of Intent for A Basic Agreement for Joint Research	Jan. 15	CI
Healios Steps In as Primary Bidder and Lender for Athersys’s Asset Sale Amidst Bankruptcy	Jan. 10	MT
Healios K.K. entered into an asset purchase agreement to acquire Substantially all assets of ABT Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC for $2.8 million.	Jan. 04	CI
Healios, Nobelpharma in Talks for Stem Cell Therapy Alliance for ARDS	Dec. 28	MT
Healios Invests in Arktus Therapeutics at Undisclosed Amount	Dec. 26	MT
Healios K.K. (TSE : 4593) agreed to acquire an unknown minority stake in Arktus Therapeutics Co., Ltd.	Dec. 21	CI
California Institute for Regenerative Medicine Awards $1 Million from the California Institute for Regenerative Medicine for Healios' Hypo-immune UDC	23-10-29	CI
Healios Secures Exclusive License for Cell Therapy Drug, Expanding Treatment for Acute Respiratory Distress Syndrome	23-10-11	MT
HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051	23-10-10	CI
HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia	23-09-13	CI
Healios K.K. Establish Subsidiary to Promote the Development	23-08-14	CI
Healios and Saisei Ventures Enter into a Letter of Intent for eNK Research and Development	23-07-10	CI
Healios Announces Establish Subsidiary for ENK Research and Development	23-07-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Healios K.K.

Equities

4593

JP3835100003

Highlights

Filters